Lisa B VanWagner1,2,3, Brittany Lapin3,4, Anton I Skaro3,4, Donald M Lloyd-Jones1, Mary E Rinella2. 1. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2. Department of Medicine, Division of Gastroenterology & Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3. Northwestern University Transplant Outcomes Research Collaborative, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 4. Department of Surgery, Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is an independent risk factor for cardiovascular disease (CVD) morbidity after liver transplantation, but its impact on CVD mortality is unknown. We sought to assess the impact of NASH on CVD mortality after liver transplantation and to predict which NASH recipients are at highest risk of a CVD-related death following a liver transplant. METHODS: Using the Organ Procurement and Transplantation Network database, we examined associations between NASH and post-liver transplant CVD mortality, defined as primary cause of death from thromboembolism, arrhythmia, heart failure, myocardial infarction or stroke. A physician panel reviewed cause of death. RESULTS: Of 48 360 liver transplants (2/2002-12/2011), 5057 (10.5%) were performed for NASH cirrhosis. NASH recipients were more likely to be older, female, obese, diabetic and have history of renal failure or prior CVD vs. non-NASH (P < 0.001 for all). Although there was no difference in overall all-cause mortality (log-rank P = 0.96), both early (30-day) and long-term CVD-specific mortality was increased among NASH recipients (Odds ratio = 1.30, 95% Confidence interval (CI): 1.02-1.66; Hazard ratio = 1.42, 95% CI: 1.07-1.41 respectively). These associations were no longer significant after adjustment for pre-transplant diabetes, renal impairment or CVD. A risk score comprising age ≥55, male sex, diabetes and renal impairment was developed for prediction of post-liver transplant CVD mortality (c-statistic 0.60). CONCLUSION: NASH recipients have an increased risk of CVD mortality after liver transplantation explained by a high prevalence of comorbid cardiometabolic risk factors that in aggregate identify those at highest risk of post-transplant CVD mortality.
BACKGROUND & AIMS:Non-alcoholic steatohepatitis (NASH) is an independent risk factor for cardiovascular disease (CVD) morbidity after liver transplantation, but its impact on CVD mortality is unknown. We sought to assess the impact of NASH on CVD mortality after liver transplantation and to predict which NASH recipients are at highest risk of a CVD-related death following a liver transplant. METHODS: Using the Organ Procurement and Transplantation Network database, we examined associations between NASH and post-liver transplant CVD mortality, defined as primary cause of death from thromboembolism, arrhythmia, heart failure, myocardial infarction or stroke. A physician panel reviewed cause of death. RESULTS: Of 48 360 liver transplants (2/2002-12/2011), 5057 (10.5%) were performed for NASH cirrhosis. NASH recipients were more likely to be older, female, obese, diabetic and have history of renal failure or prior CVD vs. non-NASH (P < 0.001 for all). Although there was no difference in overall all-cause mortality (log-rank P = 0.96), both early (30-day) and long-term CVD-specific mortality was increased among NASH recipients (Odds ratio = 1.30, 95% Confidence interval (CI): 1.02-1.66; Hazard ratio = 1.42, 95% CI: 1.07-1.41 respectively). These associations were no longer significant after adjustment for pre-transplant diabetes, renal impairment or CVD. A risk score comprising age ≥55, male sex, diabetes and renal impairment was developed for prediction of post-liver transplant CVD mortality (c-statistic 0.60). CONCLUSION: NASH recipients have an increased risk of CVD mortality after liver transplantation explained by a high prevalence of comorbid cardiometabolic risk factors that in aggregate identify those at highest risk of post-transplant CVD mortality.
Authors: Diarmaid D Houlihan; Matthew J Armstrong; Yana Davidov; James Hodson; Peter Nightingale; Ian A Rowe; Sue Paris; Bridget K Gunson; Simon B Bramhall; David J Mutimer; James M Neuberger; Philip N Newsome Journal: Liver Transpl Date: 2011-11 Impact factor: 5.799
Authors: Andrew Paul DeFilippis; Michael J Blaha; Seth S Martin; Robert M Reed; Steven R Jones; Khurram Nasir; Roger S Blumenthal; Matthew J Budoff Journal: Atherosclerosis Date: 2013-01-29 Impact factor: 5.162
Authors: F Fallo; A Dalla Pozza; N Sonino; M Lupia; F Tona; G Federspil; M Ermani; C Catena; G Soardo; L Di Piazza; S Bernardi; M Bertolotto; B Pinamonti; B Fabris; L A Sechi Journal: Nutr Metab Cardiovasc Dis Date: 2009-03-17 Impact factor: 4.222
Authors: Lucia Pacifico; Michele Di Martino; Antonio De Merulis; Mario Bezzi; John Frederick Osborn; Carlo Catalano; Claudio Chiesa Journal: Hepatology Date: 2013-12-23 Impact factor: 17.425
Authors: Lisa B VanWagner; Hongyan Ning; Maureen Whitsett; Josh Levitsky; Sarah Uttal; John T Wilkins; Michael M Abecassis; Daniela P Ladner; Anton I Skaro; Donald M Lloyd-Jones Journal: Hepatology Date: 2017-11-06 Impact factor: 17.425
Authors: Allison J Kwong; Deepika Devuni; Connie Wang; Justin Boike; Jennifer Jo; Lisa VanWagner; Marina Serper; Lauren Jones; Rajani Sharma; Elizabeth C Verna; Julia Shor; Margarita N German; Alexander Hristov; Alexander Lee; Erin Spengler; Ayman A Koteish; Gurbir Sehmbey; Anil Seetharam; Nimy John; Yuval Patel; Matthew R Kappus; Thomas Couri; Sonali Paul; Reena J Salgia; Quan Nhu; Catherine T Frenette; Jennifer C Lai; Aparna Goel Journal: Liver Transpl Date: 2020-10-13 Impact factor: 5.799
Authors: Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George Journal: Hepatol Int Date: 2020-10-01 Impact factor: 6.047
Authors: L B VanWagner; M Serper; R Kang; J Levitsky; S Hohmann; M Abecassis; A Skaro; D M Lloyd-Jones Journal: Am J Transplant Date: 2016-03-29 Impact factor: 8.086
Authors: Jaeyoun Cheong; Joseph A Galanko; Sumant Arora; Joaquin Cabezas; Nambi J Ndugga; Michael R Lucey; Paul H Hayashi; Alfred Sidney Barritt; Ramon Bataller Journal: Liver Int Date: 2016-07-04 Impact factor: 5.828